The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Real-world survival outcomes with atezolizumab versus durvalumab in extensive-stage SCLC
Apar Ganti, MD, University of Nebraska Medical Center, Omaha, NE, discusses the comparison of real-world overall survival (OS) between atezolizumab- and durvalumab-containing regimens in extensive-stage small cell lung cancer, highlighting that the median OS was similar in both groups, with 8.7 months for atezolizumab and 8.5 months for durvalumab. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
